Dusquetide for the Treatment of Behcet's Disease
← catalyst calendarSponsored by Soligenix (industry) · SNGX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8actual
Sites
1
Country
Turkey (Türkiye)
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2025-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Behçet Disease
Intervention
- Drug: Dusquetide — also filed as SGX945, SGX942
Primary outcomes
what the primary-completion date above is the date OFNumber of Oral Ulcers
measured 4 weeks
Number of Genital Ulcers
measured 4 weeks
Publications
- PMID 41400947 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SNGX's whole pipeline · Catalyst calendar · Every registered study · What changed